-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Medline, Lowers Price Target to $43

Benzinga·10/09/2026 14:55:34
Listen to the news
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.